NCT03010436View on ClinicalTrials.gov

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 15, 2017

Primary Completion Date

July 25, 2019

Study Completion Date

December 31, 2021

Conditions
Asthma
Interventions
DRUG

Benralizumab

one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.

Trial Locations (1)

80206

National Jewish Health, Denver

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

National Jewish Health

OTHER

NCT03010436 - Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study | Biotech Hunter | Biotech Hunter